A large UK study offers an encouraging picture of weight-management care delivered remotely: women with six-month measurements lost an average of 15.5% of their starting weight. The more useful question is what lay behind that figure—and whether another online service could reasonably promise the same.
The Nature Medicine paper published on 16 October 2026 followed 8,127 women who began treatment through a structured digital program. It describes substantial weight loss alongside frequent contact and clinical oversight. Because it was an observational study without a comparison group, it cannot show that remote care outperforms clinic visits or that the support program caused the results.
The denominator behind 15.5%
Of the 8,127 women starting treatment, 7,297 had weight measurements available at six months. In that group, average weight loss was 16.1 kg, or 15.5% of starting weight. The percentage is an average among people with paired measurements, not a guaranteed result for everyone who enrolled.
The women were aged 18–79, with an average starting BMI of 38.2 across the full cohort; 88% were white. Recruitment took place from November 2024 to January 2025. Treatment was overwhelmingly tirzepatide, although a small number started semaglutide. The study therefore offers much more information about this tirzepatide-dominated service than about digital delivery of every GLP-1 medicine.
The authors repeated analyses using statistical weighting to address missing measurements and reported similar estimates. That is reassuring, but the method depends on measured characteristics explaining why data are missing. It cannot rule out bias if unobserved circumstances affected both follow-up and weight change. Our guide to treatment-effect estimates explains why who gets counted matters.
What “digital care” included
This was more than an online prescription form. The published methods describe remote eligibility checks, supervised weight confirmation, home blood testing, clinician review and ongoing monitoring. Participants used their own scales, with video verification procedures. Monthly questionnaires were linked to medication refills, and concerning symptoms triggered clinical review.
Participants paid a fixed fee for medicines, testing and support; the provider partly subsidized the program during the study. That matters when judging whether the results would carry over to a differently priced service. Affordability, willingness to pay and motivation may all have influenced who joined and remained engaged.
Clinicians adjusted treatment in response to weight trajectory and tolerability. Mean weekly tirzepatide exposure reached 9.5 mg at six months. This is a description of the research cohort, not a target dose or a schedule readers should copy. The tirzepatide profile provides broader medicine context.
Why this is not a trial leaderboard
A familiar percentage can invite misleading comparisons. The SURMOUNT-1 registry describes a randomized, placebo-controlled trial in adults without type 2 diabetes, with its primary weight endpoints at 72 weeks and assigned tirzepatide dose groups. This digital cohort instead observed routine service users over six months, with individualized prescribing and no untreated or clinic-care control group.
Those differences prevent a fair ranking based on headline percentages. Nor can the tiny semaglutide exposure establish whether the two medicines performed equally. The value of this paper is evidence about delivering care to a large community cohort, alongside established trial evidence. Our guide to reading weight-loss trials gives a framework for separating those questions.
Publication is also not approval. The MHRA authorized Mounjaro for adult weight management in November 2023, subject to defined eligibility and use alongside diet and activity. This paper does not authorize a new indication or certify every online provider.
Retention and safety need separate readings
The study reported that 7,429 women, or 91.4%, remained on treatment at six months. That treatment-retention count differs from the 7,297 with six-month weight measurements. Continued dispensing and a complete outcome record are not interchangeable measures of success.
At least one side effect was reported by 62.7% of participants. Among those reporting side effects, 7.7% rated their worst symptom severe. The authors identified no serious treatment-related adverse events, but this observational reporting system cannot establish that rare serious harms never occur. Symptom severity and a medically serious adverse event are also different classifications.
The paper found lower discontinuation among people who used its symptom-management package, but use was not randomized. Differences in engagement or other characteristics could help explain that association; it does not prove the package prevented discontinuation.
What to ask about a remote service
For someone comparing services, the study suggests useful questions: Who reviews eligibility? How are weight and relevant health information checked? How quickly can concerning symptoms reach a clinician? What support remains available if treatment stops or costs change? Our weight-loss program guide expands on assessing realistic promises.
Longer follow-up is still needed to understand sustained results and what happens after treatment ends. The paper also discloses employees of the program operators, SheMed and eMed, among its authors, alongside consulting relationships. Funding came through a Chicago Community Trust donor-advised grant administered at University College London. These disclosures belong beside the findings when weighing how independently the service has been evaluated.



